REGNRegeneron Pharmaceuticals

Health care · Pharmaceuticals · Nasdaq

Employees: 15,410
Headquarters: Tarrytown, NY
CEO: Leonard S. Schleifer
Next results: around Jan 11, 2027

RevenueFY2016–25 $14.3B+1.0% FY2024: $14.2B 10-K FY2025 · XBRL Net incomeFY2016–25 $4.5B+2.1% FY2024: $4.4B 10-K FY2025 · XBRL Free cash flowFY2016–25 $4.1B+11.3% FY2024: $3.7B 10-K FY2025 · XBRL Operating marginFY2016–25 24.9%−3.2 pts 27.4% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 4, 2026 against Feb 5, 2025

Area	What changed	Source
Risk factors	22 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	2 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 4, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-05. Quoted as filed.

The full extent to which the policy changes described above will ultimately impact reimbursement levels of our marketed products, including those covered under Medicare Part B (such as EYLEA HD and EYLEA), or our product candidates that may be covered under Medicare Part B or Medicare Part D in the future, is currently unclear. In…
10-K, Item 1A

All 22 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables -7.6% vs revenue +1.0% (-8.6 pts)
✓
Cash from operations $5.0B vs net income $4.5B (FY ending 2025-12-31)
✓
Inventory +3.7% vs revenue +1.0% (+2.7 pts)
✓
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: Certain Reserves for Uncertain Tax Positions
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Oct 30, 20268-K Quarterly results 8-K item 2.02
Oct 30, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on REGN in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/REGN/export.csv") into a cell.